Related Experiment Videos
Resistance in the land of molecular cancer therapeutics
1Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94143, USA. kevins@itsa.ucsf.edu
Abstract:
The fusion tyrosine kinase Bcr-Abl plays a fundamental role in the pathogenesis of chronic myeloid leukemia (CML). Imatinib, a potent inhibitor of Bcr-Abl, has shown impressive clinical activity in CML patients. However, primary and acquired resistance occurs in many patients and is associated with reactivation of Bcr-Abl in primary leukemia cells. Studies reported over the past year have begun to elucidate the molecular basis of imatinib resistance, which may involve amplification of BCR-ABL or, more commonly, mutations that introduce amino acid substitutions into the Bcr-Abl kinase. Biochemical analysis and molecular modeling indicate that these mutant proteins retain kinase activity but are less sensitive to inhibition due to structural changes that perturb drug binding. These studies establish a paradigm for elucidating resistance to targeted therapeutics.
Insights
Resistance to imatinib therapy in chronic myeloid leukemia (CML) often stems from mutations in the Bcr-Abl kinase. These genetic alterations reduce drug sensitivity, impacting treatment effectiveness for CML patients.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The Bcr-Abl fusion tyrosine kinase is central to chronic myeloid leukemia (CML) pathogenesis.
- Imatinib is a targeted therapy effective against Bcr-Abl, but resistance limits its clinical utility.
Purpose of the Study:
- To elucidate the molecular mechanisms underlying primary and acquired imatinib resistance in CML.
- To understand how genetic alterations in Bcr-Abl affect sensitivity to targeted therapeutics.
Main Methods:
- Analysis of BCR-ABL gene amplification.
- Identification and characterization of Bcr-Abl kinase domain mutations.
- Biochemical assays to assess kinase activity and drug sensitivity.
- Molecular modeling to visualize drug-protein interactions.
Main Results:
- Imatinib resistance in CML is frequently associated with specific mutations in the Bcr-Abl kinase domain.
- These mutations alter the kinase structure, reducing imatinib binding affinity while preserving enzymatic activity.
- BCR-ABL gene amplification is another, less common, mechanism of resistance.
Conclusions:
- Mutations in Bcr-Abl represent a key mechanism of imatinib resistance in CML.
- Understanding these structural changes provides insights into targeted therapy resistance.
- This research establishes a framework for investigating resistance to other targeted cancer drugs.